推荐产品
质量水平
检测方案
≥95% (SDS-PAGE)
形式
liquid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
avoid repeated freeze/thaw cycles
运输
wet ice
储存温度
−20°C
一般描述
作为卵磷脂胆固醇酰基转移酶（LCAT）的辅助因子起作用。
来自人血浆的天然载脂蛋白A-I。作为卵磷脂胆固醇酰基转移酶（LCAT）的辅助因子起作用。它在HDL代谢中起重要作用。
包装
请参考特定浓度批号的标签。
警告
毒性：标准处理（A）
外形
在10 mM NH₄HCO₃（pH 7.4）中。
制备说明
由经认证测试对HBsAg以及HIV和HCV抗体阴性的血浆制制备而成。
重悬
初次融化后，等分并冷冻（-20°C）。在浓度≥1 mg/ml下储存。
其他说明
Bergot, C., et al. 2001.Eur. J. Biochem.268, 3523.
Pászty, C., et al. 1994.J. Clin. Invest.94, 899.
Breslow, J.L.1993.Proc.Natl.Acad.Sci. USA90, 8314.
Schultz, J.R., et al. 1992.J. Biol. Chem.267, 21630.
Walsh, A., et al. 1989.J. Biol. Chem.264, 6488.
Brewer, H.B.1986.Methods Enzymol.128, 223.
Pászty, C., et al. 1994.J. Clin. Invest.94, 899.
Breslow, J.L.1993.Proc.Natl.Acad.Sci. USA90, 8314.
Schultz, J.R., et al. 1992.J. Biol. Chem.267, 21630.
Walsh, A., et al. 1989.J. Biol. Chem.264, 6488.
Brewer, H.B.1986.Methods Enzymol.128, 223.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
免责声明
仅供研究使用在法国，在用于科研目的时（包括进口和出口活动（《公共健康法》第L 1211-1条，第2节））该产品为管制品。购买者（即最终用户）需要获得《公共健康法》法第L 1211-1条规定的法国研究部的进口授权。订购本产品即表明您确认已经获得合适的进口授权。
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Remco Franssen et al.
Cholesterol, 2012, 610741-610741 (2012-05-23)
HDL provides atheroprotection by facilitating cholesterol efflex from lipid-laden macrophages in the vessel wall. In vitro studies have suggested impaired efflux capacity of HDL following inflammatory changes. We assessed the impact of acute severe sepsis and mild chronic inflammatory disease
Mengxi Wang et al.
Oxidative medicine and cellular longevity, 2022, 2226168-2226168 (2022-12-16)
At present, due to the limitations of drug therapy targets for atherosclerosis, some patients fail to achieve satisfactory efficacy. Cholesterol efflux dysfunction and endothelial cell inflammation are considered to be important factors in the development of atherosclerosis. Peroxisome proliferator-activated receptor
Sylwia Wasiak et al.
Data in brief, 8, 1280-1288 (2016-08-30)
Apabetalone (RVX-208) inhibits the interaction between epigenetic regulators known as bromodomain and extraterminal (BET) proteins and acetyl-lysine marks on histone tails. Data presented here supports the manuscript published in Atherosclerosis "RVX-208, a BET-inhibitor for Treating Atherosclerotic Cardiovascular Disease, Raises ApoA-I/HDL
Andrzej S Pitek et al.
PloS one, 7(7), e40685-e40685 (2012-07-26)
It is now well established that the surface of nanoparticles (NPs) in a biological environment is immediately modified by the adsorption of biomolecules with the formation of a protein corona and it is also accepted that the protein corona, rather
Dean Gilham et al.
Atherosclerosis, 247, 48-57 (2016-02-13)
High density lipoproteins (HDL), through activity of the main protein component apolipoprotein A-I (ApoA-I), can reduce the risk of cardiovascular disease (CVD) by removing excess cholesterol from atherosclerotic plaque. In this study, we demonstrate that the bromodomain and extraterminal domain
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门